Nearly 35 years after the Orphan Drug Act of 1983 (ODA) became law in the United States, private investment in the development of drugs for orphan diseases continues unabated. Although the growing…
As the prevalence of chronic pain associated with numerous indications (e.g., osteoarthritis, cancer) and of idiopathic origin (e.g., chronic back pain) continues to increase in the United States…
The revolution in genomic sciences has spurred significant drug development in rare diseases, approximately 80% of which have a genetic etiology. The field of gene-based therapies, while still in…
Approximately million patients in the seven major pharmaceutical markets under study are diagnosed with epilepsy, a debilitating collection of seizure disorders that affect patients’ quality of…
The landscape of prescription drugs to manage pain in the postoperative setting represents a sizable but fragmented and challenging environment for drug marketers given the abundance of generically…
Current market-leading therapies in the U.S. COPD market will face challenges from emerging drugs, especially generic versions of Spiriva, Symbicort, and Advair. Surveyed physicians often report …
Immune checkpoint inhibitors (ICIs), including Bristol-Myers Squibb’s Opdivo and Yervoy and Merck & Co.’s Keytruda, are revolutionizing the therapeutic strategies for several cancers, notably…
The renal cell carcinoma drug market in Europe is increasingly competitive. Angiogenesis inhibitors (such as Pfizer’s Sutent and Novartis’s Votrient) and mTOR inhibitors (Pfizer’s Torisel and…
Immune checkpoint inhibitors have revolutionized the treatment of multiple oncology indications but the high costs associated with these agents present significant challenges for payers. The…
Generically available IV antibiotics commonly used as outpatient parenteral antibiotic therapy (OPAT) (e.g., IV vancomycin, daptomycin) have extensive clinical histories, benefit from strong…
Market Outlook Elevated serum potassium, commonly known as hyperkalemia, is a condition common in patients with decreased renal function and heart failure and is often exacerbated by those…
The diabetic nephropathy (DN) market is poised to expand rapidly over the next decade as late-stage therapies reach the G7 markets. These agents represent the first potential disease-modifying…
Progress in R&D and technology, regulatory and monetary incentives for advancing the development of treatments for rare diseases, and ongoing focus by the pharmaceutical market on this space are…
Numerous drugs across multiple drug classes are available for the treatment of MDD. Yet current therapies are not sufficiently effective in all patients, and those patients with TRD have…
The Parkinson’s disease (PD) market is in the midst of transformation: the first new levodopa formulation (Rytary) in over a decade has launched with more on the horizon (e.g., ND-0612, AP-CD/…